Conventional drug delivery processes take over a decade, from lead identification to clinical trials, and are very costly. In-silico drug discovery methods help reduce cost and time for drug delivery processes. Several Food and Drug Administration (FDA)-approved drugs were developed with in-silico methods.
Computational drug discovery methods facilitate the access of vast amounts of data generated and complex biological data into helpful knowledge for drug discovery.
BIS Research's healthcare experts have found in-silico drug discovery market to be one of the stable markets, and the global market is predicted to grow from $2,129.8 million in 2020 to $6,515.3 million in 2031. It is expected to grow with a CAGR of 10.52% during the forecast period 2021-2031.
Amid a rampant rise in cancer-related deaths globally, artificial intelligence is expected to help fight and prevent the spread of cancers and other infectious diseases. Therefore, more and more companies are investing in advanced technologies to combat cancer.
Several technologies are supporting the growth of the in-silico drug discovery market, some of them are artificial intelligence, graphics processing unit (GPU), and others. Advanced AI companies use computational methods such as machine learning, deep learning, and cheminformatics to deliver drugs faster.
Based on BIS Research’s report, North America currently hold the largest share of the in-silico drug discovery market. This is because of the rise in per capita income, improved healthcare infrastructure, and improved reimbursement policies in the region.
However, Europe and Asia-Pacific regions are expected to grow at the fastest CAGR during 2021-2031.
1. Increasing focus on reducing medical errors
2. Increasing technological advancements in computational biology
3. Integration of blockchain technology in interoperability
4. Increased adoption of cloud-based applications for drug discovery
Request for Sample of the Report at: https://bisresearch.com/requestsample?id=1252&type=download
1. Lack of high complexity testing centers
2. Expensive in-silico drug discovery procedures
3. Decline in the number of drugs approved
4. High capital requirement for research and development
There is massive scope for the adoption of in-silico drug discovery in developing nations. Artificial intelligence is also helping in the acceleration of the in-silico drug discovery market.
BIS Research’s healthcare team provides valuable and actionable information to its clients on trends and technologies disrupting the different segments of the healthcare industry
One of the key highlights of our market intelligence solution is the Deep Tech M-A-P™ approach. M-A-P™ includes Market, Application, and Product.
Clients at BIS Research can choose from various services, including syndicated research reports, custom research, expert consultations, individually or in any combination of the three based on their requirements.
Interested to know which new technology is emerging in your industry vertical? Get the latest market insights and studies from BIS Research. Connect with us at hello@bisresearch.com to learn more.